$3.06
-0.09 (-2.86%)
Open$3.18
Previous Close$3.15
Day High$3.20
Day Low$3.02
52W High$7.34
52W Low$2.71
Volume—
Avg Volume673.9K
Market Cap124.52M
P/E Ratio1.93
EPS$1.67
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,146.1% upside
Current
$3.06
$3.06
Target
$38.13
$38.13
$23.34
$38.13 avg
$40.06
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 159.40M | 151.50M | 22.23M |
| Net Income | 161.9K | 138.5K | -3,026,461 |
| Profit Margin | 0.1% | 0.1% | -13.6% |
| EBITDA | 126.40M | 114.13M | -4,014,681 |
| Free Cash Flow | — | — | -2,971,274 |
| Rev Growth | +5.2% | +5.2% | +14.5% |
| Debt/Equity | 0.41 | 0.41 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |